BOVESPA:GNDI3

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Notre Dame Intermédica Participações

Executive Summary

Notre Dame Intermédica Participações S.A. More Details


Snowflake Analysis

Solid track record with adequate balance sheet.

Share Price & News

How has Notre Dame Intermédica Participações's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GNDI3 is more volatile than 90% of BR stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: GNDI3's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of BR stocks.


Market Performance


7 Day Return

6.5%

GNDI3

15.2%

BR Healthcare

-0.7%

BR Market


1 Year Return

38.1%

GNDI3

48.5%

BR Healthcare

0.8%

BR Market

Return vs Industry: GNDI3 underperformed the BR Healthcare industry which returned 48.5% over the past year.

Return vs Market: GNDI3 exceeded the BR Market which returned 0.8% over the past year.


Shareholder returns

GNDI3IndustryMarket
7 Day6.5%15.2%-0.7%
30 Day29.3%28.2%4.9%
90 Day55.9%67.1%16.8%
1 Year38.5%38.1%49.6%48.5%3.5%0.8%
3 Yearn/a180.1%156.0%54.4%37.8%
5 Yearn/a747.6%622.1%219.0%164.3%

Long-Term Price Volatility Vs. Market

How volatile is Notre Dame Intermédica Participações's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Notre Dame Intermédica Participações undervalued compared to its fair value and its price relative to the market?

83.2x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: GNDI3 (R$100.31) is trading above our estimate of fair value (R$34.61)

Significantly Below Fair Value: GNDI3 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: GNDI3 is poor value based on its PE Ratio (83.2x) compared to the BR Healthcare industry average (36.8x).

PE vs Market: GNDI3 is poor value based on its PE Ratio (83.2x) compared to the BR market (17.1x).


Price to Earnings Growth Ratio

PEG Ratio: GNDI3 is poor value based on its PEG Ratio (4.1x)


Price to Book Ratio

PB vs Industry: GNDI3 is overvalued based on its PB Ratio (8.6x) compared to the BR Healthcare industry average (5.8x).


Next Steps

Future Growth

How is Notre Dame Intermédica Participações forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

20.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GNDI3's forecast earnings growth (20.2% per year) is above the savings rate (9.9%).

Earnings vs Market: GNDI3's earnings (20.2% per year) are forecast to grow slower than the BR market (27.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GNDI3's revenue (15% per year) is forecast to grow faster than the BR market (10.4% per year).

High Growth Revenue: GNDI3's revenue (15% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GNDI3's Return on Equity is forecast to be low in 3 years time (18.4%).


Next Steps

Past Performance

How has Notre Dame Intermédica Participações performed over the past 5 years?

41.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GNDI3 has high quality earnings.

Growing Profit Margin: GNDI3's current net profit margins (6.9%) are higher than last year (5.3%).


Past Earnings Growth Analysis

Earnings Trend: GNDI3's earnings have grown significantly by 41.2% per year over the past 5 years.

Accelerating Growth: GNDI3's earnings growth over the past year (69.4%) exceeds its 5-year average (41.2% per year).

Earnings vs Industry: GNDI3 earnings growth over the past year (69.4%) exceeded the Healthcare industry -0.7%.


Return on Equity

High ROE: GNDI3's Return on Equity (10%) is considered low.


Next Steps

Financial Health

How is Notre Dame Intermédica Participações's financial position?


Financial Position Analysis

Short Term Liabilities: GNDI3's short term assets (R$4.8B) exceed its short term liabilities (R$3.1B).

Long Term Liabilities: GNDI3's short term assets (R$4.8B) do not cover its long term liabilities (R$5.7B).


Debt to Equity History and Analysis

Debt Level: GNDI3's debt to equity ratio (40%) is considered high.

Reducing Debt: GNDI3's debt to equity ratio has reduced from 64.9% to 40% over the past 5 years.

Debt Coverage: GNDI3's debt is well covered by operating cash flow (31.9%).

Interest Coverage: GNDI3's interest payments on its debt are well covered by EBIT (10.9x coverage).


Balance Sheet


Next Steps

Dividend

What is Notre Dame Intermédica Participações's current dividend yield, its reliability and sustainability?

0.63%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GNDI3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GNDI3's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GNDI3's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GNDI3's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GNDI3's dividend in 3 years as they are not forecast to pay a notable one for the BR market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average board tenure


CEO

Irlau Filho (54 yo)

no data

Tenure

Mr. Irlau Machado Filho serves as Independent Director at Localiza Rent a Car S.A. since 2020. He has been a Director of Notre Dame Intermédica Participações S.A. since 2017 and serves as its Chief Executi...


Board Members

NamePositionTenureCompensationOwnership
Irlau Filho
CEO, Member of Executive Board & Directorno datano datano data
Plínio Musetti
Independent Director2yrsno datano data
Christopher Gordon
Presidentno datano datano data
Michel Freund
Director4yrsno datano data
T. O'Reillyr
Director4yrsno datano data
Wayne De Veydt
Director4yrsno datano data
José Luiz Rossi
Independent Director4yrsno datano data

4.0yrs

Average Tenure

51yo

Average Age

Experienced Board: GNDI3's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Notre Dame Intermédica Participações S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Notre Dame Intermédica Participações S.A.
  • Ticker: GNDI3
  • Exchange: BOVESPA
  • Founded: 1968
  • Industry: Managed Health Care
  • Sector: Healthcare
  • Market Cap: R$59.784b
  • Shares outstanding: 609.48m
  • Website: https://www.gndi.com.br

Number of Employees


Location

  • Notre Dame Intermédica Participações S.A.
  • Avenida Paulista, nº 867
  • Bela Vista
  • São Paulo
  • São Paulo
  • 01311-100
  • Brazil

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNDI3BOVESPA (Bolsa de Valores de Sao Paulo)YesCommon SharesBRBRLApr 2018
NTED.YOTCPK (Pink Sheets LLC)UNSPONSORED ADSUSUSDOct 2020

Biography

Notre Dame Intermédica Participações S.A. provides preventive medicine programs in Brazil. The company offers preventive medicine programs for pregnant women and the elderly, as well as the cases of patien...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/21 22:00
End of Day Share Price2021/01/21 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.